The debate surrounding right-to-try laws to allow patients access to potentially life-saving drugs hinges on safety and ethical concerns.
For decades, donor blood stem cell transplantation has been the only potential cure for severe primary immunodeficiency disorders, but it has been limited by failure and serious complication risks. Now, a trifecta of scientific advances is transforming the prognosis for children once defenseless against life-threatening infections.
The president’s FY2016 budget proposal released in February would reduce net Medicare spending by $423 billion between 2016 and 2025 and is estimated to extend the solvency of the Medical Hospital Insurance Trust Fund by approximately five years.
As obesity rates continue to climb, more needs to be understood to combat this costly epidemic that is now classified as a disease.
Eight consecutive patients on long-term, hospital-based intravenous immunoglobulin (IVIG) therapy to treat chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) (n=4) and multifocal motor neuropathy (MMN) (n=4) were switched to home-based subcutaneous immunoglobulin (SCIG).
New laws and policies are being enacted globally to stem the growth of counterfeit and adulterated drugs caused by increases in globalization and the supply chain complexity.
As the approval of biosimilars looms, debate continues over whether they should be substituted for biopharmaceuticals, how to legislate them and how they should be named.
Clinical studies using intravenous immune globulin therapy are breaking new ground when it comes to treating chronic disease; promising results are being seen in patients suffering from Alzheimer’s, autism and even diabetes.
Grifols, the world’s third largest manufacturer of plasma-based therapeutics and a leader in immunohematology and transfusion medicine diagnostics, has been patiently developing a novel approach to treatment of AD, based on plasma exchange and replacement with donor human albumin.
While the incidence of cervical cancer is on the decline in the U.S., it is still a deadly disease, so prevention and early detection are essential.
While the healthcare industry is currently experiencing an oversupply of the lifesaving immune globulin therapy, with demand growing at 6 percent to 8 percent a year, is it possible another shortage looms large?
How do these infectious agents hitch a ride with passengers, and what role does screening play in containing the public health risk posed by international air travel?
